Literature DB >> 10052869

Hypothetical framework for enhanced renal tubular secretion of drugs in cystic fibrosis.

C Woodland1, D Blowey, S Ito, M Spino, G Koren.   

Abstract

Several clinical studies demonstrate reduced serum concentrations of renally excreted drugs in patients with cystic fibrosis (CF). To explain this phenomenon, we propose a model supporting increased proximal tubular secretion of certain drugs in individuals with CF. We hypothesize that the chloride channel located on the apical surface of renal proximal tubular cells and controlled by the cystic fibrosis transmembrane conductance regulator (CFTR) operates suboptimally in CF patients, and that the abnormal CFTR decreases Cl- reabsorption, resulting in an increased concentration of Cl- in the tubular lumen. We postulate that, in an effort to maintain homeostasis, luminal Cl- moves intracellularly in exchange for organic anions. The result of stimulating this anion exchanger is an increased rate of organic anion secretion by the renal tubule. Hence, due to enhanced tubular secretion, individuals with CF demonstrate increased tubular clearance of organic anion drugs, resulting in lower steady state serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10052869     DOI: 10.1016/s0306-9877(98)90070-6

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.

Authors:  M Mulheran; C Degg; S Burr; D W Morgan; D E Stableforth
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

Authors:  Alexander A Vinks; Jan G Den Hollander; Shelley E Overbeek; Roger W Jelliffe; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.